Sandoz generic divestitures

Sandoz and Eon will divest three generic drugs as part of Novartis' acquisition of Eon: Sandoz' desipramine and orphenadrine, and Eon's rifampin. Together, the three products generated 2004 revenue of less than $5 mil., Sandoz said. The divestitures are expected to close July 22. The Federal Trade Commission is continuing to review the acquisition; Novartis has submitted a second response to the agency, and the deal is expected to close by the end of July. Novartis announced its $8.76 bil. acquisition of Eon and Hexal in February (1"The Pink Sheet" Feb. 28, 2005, p. 21)...